Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target

Longuespée, 2012, Ovarian cancer molecular pathology, Cancer Metastasis Rev, 31, 713, 10.1007/s10555-012-9383-7 Khatib, 2002, Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy, Am J Pathol, 160, 1921, 10.1016/S0002-9440(10)61140-6 Couture, 2011, On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications, Biomol Concepts, 2, 421, 10.1515/BMC.2011.034 Fugère, 2005, Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition, Trends Pharmacol Sci, 26, 294, 10.1016/j.tips.2005.04.006 Cheng, 1997, Pro-protein convertase gene expression in human breast cancer, Int J Cancer, 71, 966, 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.0.CO;2-4 Bassi, 2001, Elevated furin expression in aggressive human head and neck tumors and tumor cell lines, Mol Carcinog, 31, 224, 10.1002/mc.1057 D'Anjou, 2011, Molecular validation of PACE4 as a target in prostate cancer, Transl Oncol, 4, 157, 10.1593/tlo.10295 Juliano, 1993, Signal transduction from the extracellular matrix, J Cell Biol, 120, 577, 10.1083/jcb.120.3.577 Fu, 2003, Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells, Mol Cancer Res, 1, 569 Page, 2007, Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer, Cell Oncol, 29, 289 Couture, 2012, Role of proprotein convertases in prostate cancer progression, Neoplasia, 14, 1032, 10.1593/neo.121368 D'Anjou, 2014, Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells, Methods Mol Biol, 1103, 67, 10.1007/978-1-62703-730-3_6 Pham, 2007, Quantitative image analysis of immunohistochemical stains using a CMYK color model, Diagn Pathol, 2, 8, 10.1186/1746-1596-2-8 Kwiatkowska, 2014, Design, synthesis, and structure–activity relationship studies of a potent PACE4 inhibitor, J Med Chem, 57, 98, 10.1021/jm401457n Levesque, 2012, The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells, J Med Chem, 55, 10501, 10.1021/jm3011178 Roehm, 1991, An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT, J Immunol Methods, 142, 257, 10.1016/0022-1759(91)90114-U Vollenweider, 1996, Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases, Biochem J, 314, 521, 10.1042/bj3140521 Sundfeldt, 2003, Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule, Mol Cell Endocrinol, 202, 89, 10.1016/S0303-7207(03)00068-6 Sawada, 2008, Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target, Cancer Res, 68, 2329, 10.1158/0008-5472.CAN-07-5167 Siegel, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166 Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 Lindert, 1978, The silent killer: treatment of a patient by the oncological team, Ned Tijdschr Geneeskd, 122, 65 Seidah, 2012, The biology and therapeutic targeting of the proprotein convertases, Nat Rev Drug Discov, 11, 367, 10.1038/nrd3699 Dong, 2012, E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway, Acta Pharmacol Sin, 33, 817, 10.1038/aps.2012.30 De Marzo, 1999, E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens, Urology, 53, 707, 10.1016/S0090-4295(98)00577-9 Putzke, 2011, Metastatic progression of prostate cancer and e-cadherin: regulation by Zeb1 and Src family kinases, Am J Pathol, 179, 400, 10.1016/j.ajpath.2011.03.028 Lewis-Tuffin, 2010, Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype, PLoS One, 5, e13665, 10.1371/journal.pone.0013665 Samir, 2011, High-risk HPV infection and CIN grade correlates to the expression of c-myc, CD4+, FHIT, E-cadherin, Ki-67, and p16INK4a, J Low Genit Tract Dis, 15, 280, 10.1097/LGT.0b013e318215170c Estilo, 2009, Oral tongue cancer gene expression profiling: identification of novel potential prognosticators by oligonucleotide microarray analysis, BMC Cancer, 9, 11, 10.1186/1471-2407-9-11 Kurokawa, 2004, PCR-array gene expression profiling of hepatocellular carcinoma, J Exp Clin Cancer Res, 23, 135 Delic, 2012, Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes, Neuropathol Appl Neurobiol, 38, 201, 10.1111/j.1365-2990.2011.01207.x Bassi, 2005, PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression, Cancer Res, 65, 7310, 10.1158/0008-5472.CAN-05-1213 Mahloogi, 2002, Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4, Carcinogenesis, 23, 565, 10.1093/carcin/23.4.565 Mujoomdar, 2011, Pcsk6 mutant mice exhibit progressive loss of ovarian function, altered gene expression, and formation of ovarian pathology, Reproduction, 141, 343, 10.1530/REP-10-0451 Fugère, 2002, Inhibitors of the subtilase-like pro-protein convertases (SPCs), Curr Pharm Des, 8, 549, 10.2174/1381612023395736 Kurman, 2010, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, Am J Surg Pathol, 34, 433, 10.1097/PAS.0b013e3181cf3d79 Longuespée, 2013, Proteomic analyses of serous and endometrioid epithelial ovarian cancers – cases studies – molecular insights of a possible histological etiology of serous ovarian cancer, Proteomics Clin Appl, 7, 337, 10.1002/prca.201200079 Kleifeld, 2010, Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products, Nat Biotechnol, 28, 281, 10.1038/nbt.1611 El Ayed, 2010, MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers, Med Sci Monit, 16, BR233 Calligaris, 2013, Selected protein monitoring in histological sections by targeted MALDI-FTICR in-source decay imaging, Anal Chem, 85, 2117, 10.1021/ac302746t Longuespée, 2012, The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling, Histochem Cell Biol, 138, 141, 10.1007/s00418-012-0953-0 Franck, 2010, MALDI mass spectrometry imaging of proteins exceeding 30,000 daltons, Med Sci Monit, 16, BR293